Survival and complications of beta-thalassemia in Lebanon: A decade's experience of centralized care

Acta Haematologica

Volumn 120, Issue 2, 2008, Pages 112-116

  Charafeddine, K ^a   Isma'Eel, H ^a   Charafeddine, M ^a   Inati, A ^b,c   Koussa, S ^c   Naja, M ^a   Taher, A ^a,c  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b RAFIC HARIRI UNIVERSITY HOSPITAL   (Lebanon)

^c Chronic Care Center Hazmieh   (Lebanon)

Author keywords

Thalassemia; Complications; Lebanon; Survival

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; CHELATION THERAPY; CHILD; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; FEMALE; HEART FAILURE; HUMAN; HYPOGONADISM; HYPOTHYROIDISM; IRON OVERLOAD; LEBANON; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; THROMBOSIS;

BETA-THALASSEMIA; CAUSE OF DEATH; FERRITINS; HUMANS; IRON OVERLOAD; ITALY; LEBANON; NORTH AMERICA; PROGNOSIS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 55649083931     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000171088     Document Type: Article

References (13)

1. Haslett C, Chilvers E, Boon N, Colledge N: Davidson's Principles and Practice of Medicine, ed 19. Edinburgh, Elsevier Science, 2002, pp 928-929.
2. Inati A, Zeineh N, Isma'eel H, Koussa S, Gharzuddine W, Taher A: β-Thalassemia: the lebanese experience. Clin Lab Haematol 2006;28:217-227.
3. Rund D, Rachmilewitz E: β-Thalassemia. N Engl J Med 2005;353:1135-1146.
4. Modell B, Khan M, Darlison M: Survival in β-thalassaemia major in the UK: data from the UK thalassaemia register. Lancet 2000;355:2051-2052.
5. Taher A, El-Beshlawy A, Al Jefri A, Elalfy M, Al Zir K, Daar S, Damanhouri G, Krahn U, Pfluger D, Hadler D: Treatment with the once-daily, oral iron chelator deferasirox is effective and well tolerated in β-thalassemia patients with a high iron burden. Haematologica 2007;92:302.
6. Inati A, Taher A, Ghorra S, Koussa S, Taha M, Aoun E, Sharara AI: Efficacy and tolerability of peginterferon α-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis c virus infection. Br J Haematol 2005;130:644-646.
7. Telfer P, Coen PG, Christou S, Hadjigavriel M, Kolnakou A, Pangalou E, Pavlides N, Psiloines M, Simamonian K, Skordos G, Sitarou M, Angastiniotis M: Survival of medically treated thalassemia patients in cyprus: trends and risk factors over the period 1980-2004. Haematologica 2006;91:1187-1192.
8. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR: Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med 1994;331:574-578.
9. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Origa R, Piga A, Romeo MA, Zhao H, Cnaan A: Survival and complications in thalassemia. Ann NY Acad Sci 2005;1054:40-47.
10. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR: Complications of β-thalassemia major in North America. Blood 2004;104:34-39.
11. Irani-Hakime N, Musharrafieh U, Samaha H, Almawi WY: Prevalence of antibodies against hepatitis B virus and hepatitis C virus among blood donors in Lebanon, 1997-2003. Am J Infect Control 2006;34:241-243.
12. Ansaldi F, Bruzzone B, Salmaso S, Rota MC, Durando P, Gasparini R, Icardi G: Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. J Med Virol 2005;76:327-332.
13. St Pierre TG, Clark PR, Chua-anusorn W, Fleming AJ, Jeffrey GP, Olynyk JK, Pootrakul P, Robins E, Lindeman R: Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005;105:855-861.